Quintela Fandiño, Miguel Angel miguel.quintela@uam.es

Actividades

Usefulness and real-world outcomes of next generation sequencing testing in patients with cancer: an observational study on the impact of selection based on clinical judgement

  • Colomer R
  • Miranda J
  • Romero-Laorden N
  • Hornedo J
  • González-Cortijo L
  • Mouron S
  • Bueno MJ
  • Mondéjar R
  • Quintela-Fandino M
... Ver más Contraer

Eclinicalmedicine - 1/6/2023

10.1016/j.eclinm.2023.102029 Ver en origen

  • ISSN 25895370

Tumor P70S6K hyperactivation is inversely associated with tumor-infiltrating lymphocytes in triple-negative breast cancer

  • Jimeno, R.
  • Mouron, S.
  • Salgado, R.
  • Loi, S.
  • Pérez-Mies, B.
  • Sánchez-Bayona, R.
  • Manso, L.
  • Martínez, M.
  • Garrido-García, A.
  • Serrano-Pardo, R.
  • Colomer, R.
  • Quintela-Fandino, M.
... Ver más Contraer

Clinical & Translational Oncology (p. 1124-1131) - 1/4/2023

Editor: Springer Science and Business Media Deutschland GmbH

10.1007/s12094-022-03006-3 Ver en origen

  • ISSN 1699048X
  • ISSN/ISBN 1699-3055

p27(Kip1) V109G as a biomarker for CDK4/6 inhibitors indication in hormone receptor-positive breast cancer

  • Mouron, S
  • Bueno, MJ
  • Munoz, M
  • Torres, R
  • Rodriguez, S
  • Apala, JV
  • Silva, J
  • Sanchez-Bayona, R
  • Manso, L
  • Guerra, J
  • Rodriguez-Lajusticia, L
  • Malon, D
  • Malumbres, M
  • Quintela-Fandino, M
... Ver más Contraer

Jnci Cancer Spectrum - 1/4/2023

10.1093/jncics/pkad014

  • ISSN 25155091
  • iMarina

Phosphoproteomic analysis of neoadjuvant breast cancer suggests that increased sensitivity to paclitaxel is driven by CDK4 and filamin A

  • Mouron S
  • Bueno MJ
  • Lluch A
  • Manso L
  • Calvo I
  • Cortes J
  • Garcia-Saenz JA
  • Gil-Gil M
  • Martinez-Janez N
  • Apala JV
  • Caleiras E
  • Ximénez-Embún P
  • Muñoz J
  • Gonzalez-Cortijo L
  • Murillo R
  • Sánchez-Bayona R
  • Cejalvo JM
  • Gómez-López G
  • Fustero-Torre C
  • Sabroso-Lasa S
  • Malats N
  • Martinez M
  • Moreno A
  • Megias D
  • Malumbres M
  • Colomer R
  • Quintela-Fandino M
... Ver más Contraer

Nature Communications - 1/12/2022

10.1038/s41467-022-35065-z Ver en origen

  • ISSN 20411723

Prolonged estrogen deprivation triggers a broad immunosuppressive phenotype in breast cancer cells

  • Hühn D
  • Martí-Rodrigo P
  • Mouron S
  • Hansel C
  • Tschapalda K
  • Porebski B
  • Häggblad M
  • Lidemalm L
  • Quintela-Fandino M
  • Carreras-Puigvert J
  • Fernandez-Capetillo O
... Ver más Contraer

Molecular Oncology (p. 148-165) - 1/1/2022

10.1002/1878-0261.13083 Ver en origen

  • ISSN 15747891

Mitochondrial Inhibition: a Treatment Strategy in Cancer?

  • Bueno, Maria J.
  • Ruiz-Sepulveda, Jose L.
  • Quintela-Fandino, Miguel;

Current Oncology Reports - 1/4/2021

10.1007/s11912-021-01033-x Ver en origen

  • ISSN 15233790

FGFR1 amplification or overexpression and hormonal resistance in luminal breast cancer: rationale for a triple blockade of ER, CDK4/6, and FGFR1

  • Mouron S, Manso L, Caleiras E, Rodriguez-Peralto JL, Rueda OM, Caldas C, Colomer R, Quintela-Fandino M, Bueno MJ

Breast Cancer Research (p. 21-21) - 1/12/2021

10.1186/s13058-021-01398-8

  • ISSN 14655411
  • iMarina

Glutamine-Directed Migration of Cancer-Activated Fibroblasts Facilitates Epithelial Tumor Invasion

  • Mestre-Farrera A
  • Bruch-Oms M
  • Peña R
  • Rodríguez-Morato J
  • Alba-Castellon L
  • Comerma L
  • Quintela-Fandino M
  • Duñach M
  • Baulida J
  • Pozo OJ
  • de Herreros AG
... Ver más Contraer

Cancer Research (p. 438-451) - 15/1/2021

10.1158/0008-5472.can-20-0622 Ver en origen

  • ISSN 00085472

When should we order a next generation sequencing test in a patient with cancer?

  • Colomer R, Mondejar R, Romero-Laorden N, Alfranca A, Sanchez-Madrid F, Quintela-Fandino M

Eclinicalmedicine (p. 100487-100487) - 1/8/2020

10.1016/j.eclinm.2020.100487 Ver en origen

  • ISSN 25895370

Coordinated signals from PARP-1 and PARP-2 are required to establish a proper T cell immune response to breast tumors in mice

  • Moreno-Lama L
  • Galindo-Campos MA
  • Martínez C
  • Comerma L
  • Vazquez I
  • Vernet-Tomas M
  • Ampurdanés C
  • Lutfi N
  • Martin-Caballero J
  • Dantzer F
  • Quintela-Fandino M
  • Ali SO
  • Jimeno J
  • Yélamos J
... Ver más Contraer

Oncogene (p. 2835-2843) - 26/3/2020

10.1038/s41388-020-1175-x Ver en origen

  • ISSN 09509232

Este/a investigador/a no tiene libros.

Este/a investigador/a no tiene capítulos de libro.

Phase I clinical trial of neoadjuvant BIBF1120 plus weekly paclitaxel (P) in early HER-2 negative breast cancer. CNIO-BR-01-2010 GEICAM 2010-10 study

  • Quintela-Fandino, M.
  • Urruticoechea, A.
  • Guerra, J.
  • Gil, M.
  • Gonzalez-Martin, A.
  • Marquez, R.
  • Hernandez-Agudo, E.
  • Rodriguez-Martin, C.
  • Gil, M.
  • Bratos, R.
  • Escudero, M. J.
  • Colomer, R.;
... Ver más Contraer

Cancer Research - 15/12/2013

10.1158/0008-5472.sabcs13-pd5-8 Ver en origen

  • ISSN 00085472

Este/a investigador/a no tiene documentos de trabajo.

A Phase I Study Investigating AZD8186, a Potent and Selective Inhibitor of PI3K?/?, in Patients with Advanced Solid Tumors

  • Choudhury AD, Higano CS, de Bono JS, Cook N, Rathkopf DE, Wisinski KB, Martin-Liberal J, Linch M, Heath EI, Baird RD, García-Carbacho J, Quintela-Fandino M, Barry ST, de Bruin EC, Colebrook S, Hawkins G, Klinowska T, Maroj B, Moorthy G, Mortimer PG, Moschetta M, Nikolaou M, Sainsbury L, Shapiro GI, Siu LL, Hansen AR

Clinical Cancer Research (p. 2257-2269) - 1/1/2022

10.1158/1078-0432.ccr-21-3087 Ver en origen

  • ISSN 15573265

Este/a investigador/a no tiene proyectos de investigación.

Triple negative breast cancer kinome-taxonomy, prognostic and therapeutics: role of polynucleotide kinase-phosphatase

  • QUINTELA FANDIÑO, MIGUEL ANGEL (Director) Doctorando: Fernández Gaitero, Sara

4/3/2021

  • iMarina

Este/a investigador/a no tiene patentes o licencias de software.

Última actualización de los datos: 18/03/24 14:43